China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 721,044 shares, a growth of 999.1% from the September 30th total of 65,603 shares. Approximately 157.1% of the shares of the company are sold short. Based on an average daily volume of 52,120,891 shares, the days-to-cover ratio is currently 0.0 days.
China SXT Pharmaceuticals Stock Performance
Shares of SXTC traded down $0.56 during mid-day trading on Monday, hitting $3.54. 188,145 shares of the company’s stock were exchanged, compared to its average volume of 64,702,860. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a 52 week low of $3.37 and a 52 week high of $8,375,880.00. The stock’s 50-day simple moving average is $209.45 and its 200-day simple moving average is $37,799.87.
Wall Street Analysts Forecast Growth
SXTC has been the topic of several recent research reports. Weiss Ratings upgraded China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Wall Street Zen raised shares of China SXT Pharmaceuticals to a “sell” rating in a research report on Saturday, August 22nd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on SXTC
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc (NASDAQ: SXTC) is a pharmaceutical company based in Taizhou, Jiangsu Province, China. The company develops, manufactures and sells traditional Chinese medicine products, serving customers primarily in the Chinese market.
Its product portfolio includes prescription and over-the-counter traditional Chinese medicines, as well as health-related products and dietary supplements. The company’s operations encompass the preparation of herbal ingredients and the production, marketing and distribution of finished traditional Chinese medicine products.
China SXT Pharmaceuticals was established in 2005 and completed its initial public offering on the Nasdaq Capital Market in 2019.
Further Reading
- Five stocks we like better than China SXT Pharmaceuticals
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
